Cargando…

Validation of an HPLC–MS/MS Method for the Determination of Plasma Ticagrelor and Its Active Metabolite Useful for Research and Clinical Practice

Ticagrelor is an antiplatelet agent which is extensively metabolized in an active metabolite: AR-C124910XX. Ticagrelor antagonizes P2Y12 receptors, but recently, this effect on the central nervous system has been linked to the development of dyspnea. Ticagrelor-related dyspnea has been linked to per...

Descripción completa

Detalles Bibliográficos
Autores principales: Lagoutte-Renosi, Jennifer, Royer, Bernard, Rabani, Vahideh, Davani, Siamak
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7827928/
https://www.ncbi.nlm.nih.gov/pubmed/33429903
http://dx.doi.org/10.3390/molecules26020278
_version_ 1783640886490431488
author Lagoutte-Renosi, Jennifer
Royer, Bernard
Rabani, Vahideh
Davani, Siamak
author_facet Lagoutte-Renosi, Jennifer
Royer, Bernard
Rabani, Vahideh
Davani, Siamak
author_sort Lagoutte-Renosi, Jennifer
collection PubMed
description Ticagrelor is an antiplatelet agent which is extensively metabolized in an active metabolite: AR-C124910XX. Ticagrelor antagonizes P2Y12 receptors, but recently, this effect on the central nervous system has been linked to the development of dyspnea. Ticagrelor-related dyspnea has been linked to persistently high plasma concentrations of ticagrelor. Therefore, there is a need to develop a simple, rapid, and sensitive method for simultaneous determination of ticagrelor and its active metabolite in human plasma to further investigate the link between concentrations of ticagrelor, its active metabolite, and side effects in routine practice. We present here a new method of quantifying both molecules, suitable for routine practice, validated according to the latest Food and Drug Administration (FDA) guidelines, with a good accuracy and precision (<15% respectively), except for the lower limit of quantification (<20%). We further describe its successful application to plasma samples for a population pharmacokinetics study. The simplicity and rapidity, the wide range of the calibration curve (2–5000 µg/L for ticagrelor and its metabolite), and high throughput make a broad spectrum of applications possible for our method, which can easily be implemented for research, or in daily routine practice such as therapeutic drug monitoring to prevent overdosage and occurrence of adverse events in patients.
format Online
Article
Text
id pubmed-7827928
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-78279282021-01-25 Validation of an HPLC–MS/MS Method for the Determination of Plasma Ticagrelor and Its Active Metabolite Useful for Research and Clinical Practice Lagoutte-Renosi, Jennifer Royer, Bernard Rabani, Vahideh Davani, Siamak Molecules Article Ticagrelor is an antiplatelet agent which is extensively metabolized in an active metabolite: AR-C124910XX. Ticagrelor antagonizes P2Y12 receptors, but recently, this effect on the central nervous system has been linked to the development of dyspnea. Ticagrelor-related dyspnea has been linked to persistently high plasma concentrations of ticagrelor. Therefore, there is a need to develop a simple, rapid, and sensitive method for simultaneous determination of ticagrelor and its active metabolite in human plasma to further investigate the link between concentrations of ticagrelor, its active metabolite, and side effects in routine practice. We present here a new method of quantifying both molecules, suitable for routine practice, validated according to the latest Food and Drug Administration (FDA) guidelines, with a good accuracy and precision (<15% respectively), except for the lower limit of quantification (<20%). We further describe its successful application to plasma samples for a population pharmacokinetics study. The simplicity and rapidity, the wide range of the calibration curve (2–5000 µg/L for ticagrelor and its metabolite), and high throughput make a broad spectrum of applications possible for our method, which can easily be implemented for research, or in daily routine practice such as therapeutic drug monitoring to prevent overdosage and occurrence of adverse events in patients. MDPI 2021-01-08 /pmc/articles/PMC7827928/ /pubmed/33429903 http://dx.doi.org/10.3390/molecules26020278 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Lagoutte-Renosi, Jennifer
Royer, Bernard
Rabani, Vahideh
Davani, Siamak
Validation of an HPLC–MS/MS Method for the Determination of Plasma Ticagrelor and Its Active Metabolite Useful for Research and Clinical Practice
title Validation of an HPLC–MS/MS Method for the Determination of Plasma Ticagrelor and Its Active Metabolite Useful for Research and Clinical Practice
title_full Validation of an HPLC–MS/MS Method for the Determination of Plasma Ticagrelor and Its Active Metabolite Useful for Research and Clinical Practice
title_fullStr Validation of an HPLC–MS/MS Method for the Determination of Plasma Ticagrelor and Its Active Metabolite Useful for Research and Clinical Practice
title_full_unstemmed Validation of an HPLC–MS/MS Method for the Determination of Plasma Ticagrelor and Its Active Metabolite Useful for Research and Clinical Practice
title_short Validation of an HPLC–MS/MS Method for the Determination of Plasma Ticagrelor and Its Active Metabolite Useful for Research and Clinical Practice
title_sort validation of an hplc–ms/ms method for the determination of plasma ticagrelor and its active metabolite useful for research and clinical practice
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7827928/
https://www.ncbi.nlm.nih.gov/pubmed/33429903
http://dx.doi.org/10.3390/molecules26020278
work_keys_str_mv AT lagoutterenosijennifer validationofanhplcmsmsmethodforthedeterminationofplasmaticagreloranditsactivemetaboliteusefulforresearchandclinicalpractice
AT royerbernard validationofanhplcmsmsmethodforthedeterminationofplasmaticagreloranditsactivemetaboliteusefulforresearchandclinicalpractice
AT rabanivahideh validationofanhplcmsmsmethodforthedeterminationofplasmaticagreloranditsactivemetaboliteusefulforresearchandclinicalpractice
AT davanisiamak validationofanhplcmsmsmethodforthedeterminationofplasmaticagreloranditsactivemetaboliteusefulforresearchandclinicalpractice